Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10467-10478

  Li, Quan ^a   Liu, Long ^b   Li, Weiming ^b  

^a Department of Oncology Xiangyang Central Hospital The Affiliated Hospital of Hubei College of Arts and Sciences   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Circulating microRNAs; Diagnostic value; Hematologic cancers; Meta analysis

Indexed keywords

DNA; MICRORNA;

BLOOD; DIAGNOSTIC USE; GENETICS; HEMATOLOGIC NEOPLASMS; HUMAN; META ANALYSIS;

DNA, NEOPLASM; HEMATOLOGIC NEOPLASMS; HUMANS; MICRORNAS;

EID: 84922391907     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2364-4     Document Type: Article

References (47)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–907. doi:10.1016/S0140-6736(06)69780-8.
2. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol. 2007;18 Suppl 1:3–8. doi:10.1093/annonc/mdl443.
3. Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004:98–117. doi:10.1182/asheducation-2004.1.98.
4. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009;2:23. doi:10.1186/1756-8722-2-23.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
6. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35. doi:10.1007/978-3-540-85772-3_2.
7. Orfao A, Lopez A, Flores J, Almeida J. Diagnosis of hematological malignancies: new applications for flow cytometry. Hematol (EHA Educ Program). 2006;2:6–13.
8. Belov L, Huang P, Barber N, Mulligan SP, Christopherson RI. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics. 2003;3:2147–54. doi:10.1002/pmic.200300599.
9. Ruiz-Arguelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A. Report on the second Latin American consensus conference for flow cytometric immunophenotyping of hematological malignancies. Cytometry B Clin Cytom. 2006;70:39–44. doi:10.1002/cyto.b.20083.
10. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1:118–29. doi:10.1038/35101072.
11. Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W, et al. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol. 2010;85:236–42. doi:10.1111/j.1600-0609.2010.01475.x.
12. Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma. 2013;54:189–91. doi:10.3109/10428194.2012.704030.
13. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69. doi:10.1038/nrc1840.
14. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3:3694. doi:10.1371/journal.pone.0003694.
15. Lin S, Pan L, Guo S, Wu J, Jin L, Wang JC, et al. Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysis. PLoS One. 2013;8:59532. doi:10.1371/journal.pone.0059532.
16. Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117:3140–6. doi:10.1182/blood-2010-09-308684.
17. Fang C, Zhu DX, Dong HJ, Zhou ZJ, Wang YH, Liu L, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol. 2012;91:553–9. doi:10.1007/s00277-011-1350-9.
18. Guo HQ, Huang GL, Guo CC, Pu XX, Lin TY. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. Dis Markers. 2010;29:251–8. doi:10.3233/dma-2010-0755.
19. Ohyashiki K, Umezu T, Yoshizawa S, Ito Y, Ohyashiki M, Kawashima H, et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin’s lymphoma. PLoS One. 2011;6:16408. doi:10.1371/journal.pone.0016408.
20. Hao M, Zang M, Qin Y, Yang W, Feng X, Xu Y, et al. Circulating MIR-19A and MIR-92A in serum as potential biomarkers for detecting multiple myeloma. Clin Lymphoma Myeloma and Leuk. 2013;13:198–9.
21. Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99:511–8. doi:10.3324/haematol.2013.093500.
22. Zhi F, Cao X, Xie X, Wang B, Dong W, Gu W, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One. 2013;8:56718. doi:10.1371/journal.pone.0056718.
23. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8. doi:10.1073/pnas.0804549105.
24. Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010;10:297–308. doi:10.1586/erm.10.11.
25. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101:2087–92. doi:10.1111/j.1349-7006.2010.01650.x.
26. Xie HT, Chu ZX, Wang H. Serum microRNA expression profile as a biomarker in diagnosis and prognosis of acute myeloid leukemia. J Clin Pediatr. 2012;30:421–4.
27. Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012;2:53. doi:10.1038/bcj.2011.51.
28. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36. doi:10.7326/0003-4819-155-8-201110180-00009.
29. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31. doi:10.1186/1471-2288-6-31.
30. Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, Badran R, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 2013;11:31. doi:10.1186/1479-5876-11-31.
31. Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z, Xia LY, et al. miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep. 2012;39:2713–22. doi:10.1007/s11033-011-1026-5.
32. Mao X, Sun Y, Tang J. Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci. 2014;35:233–8.
33. Hao M, Zang M, Yu Q, Fei L, Yang W, Feng X et al. Serum miR-4254, miR-19a and miR-33b are potential markers for diagnosis and prognostic evaluation in multiple myeloma. Blood. 2013;122.
34. Qu X, Zhao M, Wu S, Yu W, Xu J, Xu J et al. Circulating microrna 483-5p in multiple myeloma as a novel biomarker for diagnosis and predicting survival. Blood. 2013;122.
35. Frankfurt O, Licht JD, Tallman MS. Molecular characterization of acute myeloid leukemia and its impact on treatment. Curr Opin Oncol. 2007;19:635–49. doi:10.1097/CCO.0b013e3282f10e55.
36. Haferlach T, Bacher U, Haferlach C, Kern W, Schnittger S. Insight into the molecular pathogenesis of myeloid malignancies. Curr Opin Hematol. 2007;14:90–7. doi:10.1097/MOH.0b013e3280168490.
37. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc. 2006;81:247–60. doi:10.4065/81.2.247.
38. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116:5103–10. doi:10.1182/blood-2010-07-259333.
39. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.
40. Wittmann J, Jack HM. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta Rev Cancer. 1806;2010:200–7.
41. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721–6. doi:10.1200/JCO.2009.24.9342.
42. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One. 2010;5:e13735. doi:10.1371/journal.pone.0013735.
43. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011;57:833–40. doi:10.1373/clinchem.2010.157198.
44. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115:3842–7. doi:10.1002/cncr.24440.
45. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55. doi:10.1186/1479-5876-10-55.
46. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5. doi:10.1111/j.1365-2141.2008.07077.x.
47. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118–26. doi:10.1002/ijc.25007.